MannKind has just logged a sharp move over the past month, which brings a fresh spotlight on whether the current share price lines up with the cash flows the business can realistically produce. With the stock now changing hands at recent levels around that move, the question is how much of its future cash generation is already reflected in the valuation.
- The share price has climbed 37.4% over the past month, which raises the stakes on whether recent optimism matches the cash MannKind can generate over time.
- The company’s profile as a commercial-stage biotech with significant R&D needs can shape both the timing and consistency of future cash flows, which feeds directly into what long term holders are paying for today.
- If you'd rather focus on sales, this one's for you. See why MannKind's 3.3x P/S tells a different valuation story.
The issue now is whether MannKind’s present market value is supported by its cash flows when viewed through a Discounted Cash Flow (DCF) lens.
If you are weighing MannKind through the lens of its cash flows, it can help to compare it with other businesses that also screen for valuation quality using 32 high quality undervalued stocks.
Is MannKind Fairly Priced on Cash Flow?
The Discounted Cash Flow (DCF) model used here applies a 2 Stage Free Cash Flow to Equity approach to convert MannKind’s potential future cash generation into today’s dollars. Recent trailing twelve month free cash flow shows an outflow of $78.84 million, so the valuation depends on the expectation that the business may eventually move from cash burn to more durable inflows over time.
Analysts feeding into this framework are assuming MannKind’s free cash flow shifts into positive territory and then grows in the coming decade, with projected annual cash generation in the tens of millions of dollars and gradually rising. Those future figures, when discounted back and compared with today’s share price of $4.19, lead to an estimated intrinsic value that the model suggests is broadly in line with where the stock trades now. Find out what MannKind could be worth using our Discounted Cash Flow (DCF) estimate.
The MannKind Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the DCF puzzle leaves off by laying out the specific paths for MannKind’s growth, profitability and earnings that would make today’s valuation look either stretched or conservative. They use a set of scenario-style views that each ties its number to a concrete stance on how revenue potential, cost structure and key risks might evolve, so you can return to those assumptions as fresh information is released.
One of the top narratives on MannKind: 67% undervalued
This Narrative is the bullish analyst Narrative on Simply Wall St, built on the most optimistic analyst price target and forecasts, not one person's view.
"The current valuation, together with the view among some market participants that MannKind is undervalued, suggests that the share price may not yet fully reflect the revenue contribution from Afrezza and Furoscix..."
Discover why this Narrative puts MannKind at 67% undervalued.
For MannKind, who is steering the ship and on what terms
Valuation only tells you what the market is paying today. It does not reveal who is making the key calls inside MannKind or how their pay packets line up with your interests. See who runs MannKind and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com